Nagoya University spins out iBody venture

The company will commercialize their "ecobody system" developed by Professor Hideo NAKANO. From singularized B-cells obtained from a trace amount of blood, mAbs can be produced in a cell-free E. coli system, and mAbs with high affinity and high selectivity for a target antigen are selected using recombinant E. coli. The whole process takes only 2 days.

Source: Nikkei Biotech news release, May 16, 2018

Request a quote for deeper information from

© 2018 Window to Japan - Bio 4 Business - Imprint